Brexit is giving rise to great uncertainty regarding the future of life science research and development of new medicines in the UK. This paper, published in this month’s Journal of Clinical Pharmacology and Therapeutics outlines the potential public health issues and commercial issues to all stakeholders in the Pharmaceutical industry by the disruption to the European life science products regulatory framework. Dr Peter Feldschreiber and the team at 4 New Square will be happy to advise on these issues.
